GlobalData analysed all terminated trials within the Clinical Trials Database and found the top five therapy areas by trial count to be Oncology, Central Nervous System, Cardiovascular, Infectious Disease, and Metabolic Disorders, in descending order.
Go deeper with GlobalData
The largest phase of termination occurred in Phase II in all therapeutic areas (Figure 1), as well as across all terminated trials. Overall, Phase II accounted for 50% of all terminated trials and Oncology was the only therapy area that exceeded this, where 65% of all Phase II trials were terminated.
The biggest reason for trial discontinuation in Oncology was “low accrual rate,” at 35% of all terminated trials with reasons given. This was followed by “unspecified” at 25%, “other” at 16%, “lack of efficacy” at 10%, and “adverse events” at 6% rounding out the top five reasons.
Image: Top five therapy areas in terminated trials. Credit: GlobalData.
